(12) Patent Application Publication (10) Pub. No.: US 2004/0016005 A1 Karatzas Et Al
Total Page:16
File Type:pdf, Size:1020Kb
US 2004001.6005A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0016005 A1 KaratZas et al. (43) Pub. Date: Jan. 22, 2004 (54) PRODUCTION OF Related U.S. Application Data BUTYRYLCHOLINESTERASES IN TRANSGENIC MAMMALS (60) Provisional application No. 60/344.295, filed on Dec. 21, 2001. (76) Inventors: Costas N. Karatzas, Quebec (CA); Publication Classification Yue Jin Huang, Quebec (CA), (51) Int. Cl. ................................................ A01K 67/027 Anthoula Lazaris, Quebec (CA) (52) U.S. Cl. .................................... 800/7; 800/14; 800/18 (57) ABSTRACT Correspondence Address: DARBY & DARBY PC. The present invention provides methods for the large-scale P. O. BOX 5257 production of recombinant butyrylcholinesterase in cell cul NEW YORK, NY 10150-5257 (US) ture, and in the milk and/or urine of transgenic mammals. The recombinant butyrylcholinesterases of this invention (21) Appl. No.: 10/326,892 can be used to treat and/or prevent organophosphate pesti cide poisoning, nerve gas poisoning, cocaine intoxication, (22) Filed: Dec. 20, 2002 and Succinylcholine-induced apnea. Patent Application Publication Jan. 22, 2004 Sheet 2 of 13 US 2004/001.6005 A1 90 CTTCTGAATGAAGCATTTGTTGTCCCCTATGGGACTCCTTTGTCAGTAAACTTTGGTCCG 30 L. L N E A F W V P Y G T P L S. V N F G P 96.1 ACCCTGGATGGTGATTTTCTCACTGACATGCCAGACATATTACTTGAACTTGGACAATTT 321 T W D G D F L T D M P D T L L E L G Q F 1021 AAAAAAACCCAGATTTTGGTGGGTGTTAATAAAGATGAAGGGACAGCTTTTTTAGTCTAT 341 K K T C I L W G V N K D E G T A F L V Y O8. GGTGCTCCTGGCTTCAGCAAAGATAACAATAGTATCATAACTAGAAAAGAATTTCAGGAA 361 G A P G F S K D N N S I I T R K E F O E 1141 GGTTTAAAAATATTTTTTCCAGGAGTGAGTGAGTTTGGAAAGGAATCCATCCTTTTTCAT 381 G K. T. F. F. P G W S E E G K E S I L. F. H. 12 Ol TACACAGACTGGGTAGATGATCAGAGACCTGAAAACTACCGTGAGGCCTTGGGTGATGTT 4 Ol Y T D W W D D Q R P E N Y R E A L G D V 1261 GTTGGGGATTATAATTTCATATGCCCTGCCTTGGAGTTCACCAAGAAGTTCTCAGAATGG 421 W G D Y N F I C P A T E F T K K F S E W 321 GGAAATAATGCCTTTTTCTACTATTTTGAACACCGATCCTCCAAACTTCCGTGGCCAGAA 441 G N N A F F Y Y F E H R S S K L P W P E 138 TGGATGGGAGTGATGCATGGCTATGAAATTGAATTTGTCTTTGGTTTACCTCTGGAAAGA 461 W M G W M H G Y E E. F. W. F. G L P L E R. 1441 AGAGATAATTACACAAAAGCCGAGGAAATTTTGAGTAGATCCATAGTGAAACGGTGGGCA 481 R D N Y T K A E E L L S R S I V K R W A 5 O1. AATTTTGCAAAATATGGGAATCCAAATGAGACT CAGAACAATAGCACAAGCTGGCCTGTC 5 O. N F A K Y G N P N E T Q N N S T S W P V 156 TTCAAAAGCACTGAACAAAAATATCTAACCTTGAATACAGAGTCAACAAGAATAATGACG 521 F K S T E Q K. Y. L T L N T E S T R I M T. 1621 AAACTACGTGCTCAACAATGTCGATTCTGGACACATTTTTTCCAAAAGTCTGGAAATG 541 K L R A Q O C R F W T S F F P K V L E M 168 ACAGGAAATATTGATGAAGCAGAATCGGGAGTGGAAAGCAGGATTCCATCGCTGGAACAAT 56 T G. N. D E A E W E W K. A. G F PH. R. W. N. N. 1741 TACATGATGGACTGGAAAAATCAATTTAACGATTACACTAGCAAGAAAGAAAGTTGTGTG 58 Y M M D W. K. N. Q F N D Y T S K K E S C V 18O GGTCTCTAA 60 G k FIGURE 1B Patent Application Publication Jan. 22, 2004 Sheet 4 of 13 US 2004/001.6005 A1 -- Tetr BChE Dimer BChE-hSA Ca - Monomer BChE-hSA FIGURE 3 Patent Application Publication Jan. 22, 2004 Sheet 5 of 13 US 2004/0016005 A1 mature protein 214 ATG (130) 1 TAA (1938) Y. - Noti (16908) XXXXXXXXXXXXXXXXXXXX pUC18/BCNN 15595bp XhoI + B-casein SS Xho PCR 5' B-casein HH 1. XhoI digestion 2. Cloning into pCEM-T 1. Ligation 2. Transformation Not I 3' 3-casein (2219) pBCNN/BChE 17399bp XhoI (10675) 5' 3-casein FIGURE 4 Patent Application Publication Jan. 22, 2004 Sheet 6 of 13 US 2004/001.6005 A1 BChE encoding sequence a -exxx xxx xxxx xxxas YS 1. 2 -3 4 56 N7 8 9 \ ATG STOP 5' UTR (47nt) Goat 3-casein genomic locus 1000bp FIGURES Patent Application Publication Jan. 22, 2004 Sheet 7 of 13 US 2004/001.6005 A1 Dimer rBChE -Ge. < Endogenous BChE dimer Monomer rBChE - Ge. FIGURE 6 Patent Application Publication Jan. 22, 2004 Sheet 8 of 13 US 2004/001.6005 A1 1- Tetramer BChE -H Dimer BChE *H Monomer BChE FIGURE 7 Patent Application Publication Jan. 22, 2004 Sheet 9 of 13 US 2004/001.6005 A1 Monomer BChE FIGURE 8 Patent Application Publication Jan. 22, 2004 Sheet 10 of 13 US 2004/0016005 A1 Noti (14920) WAP 3' Not I (2228) WAP Coding Insulator pWAP/BChE 15583bp BamHI (4661) Pme (10706) Signal Sequence FIGURE 9 Patent Application Publication Jan. 22, 2004 Sheet 11 of 13 US 2004/001.6005 A1 rf 4 \c ve c s g 2R O \d a & &S& &XXXXXC &SXXXXX r &S& CXCXXC O A 3. wit S y c eu A. C r e al Patent Application Publication Jan. 22, 2004 Sheet 12 of 13 US 2004/0016005 A1 Not I UM 3 gift XhoI Fsel Sgfl Insulator pUM/5S13 f 14kb (4647) BChE PCR productOOC Sgf -Digest with Fsel & Sgfl MS -Ligate FSe UM promoter UMSS Not I UM 3 Insulator pUM/BChE (4647) Sgf BChE UM SS UM promoter FIGURE 11 Patent Application Publication Jan. 22, 2004 Sheet 13 of 13 US 2004/0016005 A1 Not I UM3 Insulator Ascl FSel pUM/BChEmod AscI Sgf Mouse UPI PCR product UPII Promoter BChE UM promoter Digested with Asci-Fsel & ligation Sgfl Notl Insulator III.III.IIII pUPII/BChE1 nt Mouse UPII PCR product 14kb AscI 3 genomic sequence Digested with Sgfl-Notl & ligation UPII promoter Not I UPI 3. Insulator pUPII/BChE 14kb AscL SgfI W. BChE FSe s", , , , . .", UPII promoter UPII SS FIGURE 12 US 2004/001.6005 A1 Jan. 22, 2004 PRODUCTION OF BUTYRYLCHOLINESTERASES acetylcholine acetylhydrolase, (EC 3.1.1.7). Those enzymes IN TRANSGENIC MAMMALS which preferentially hydrolyze other types of esterS Such as butyrylcholine, and whose enzymatic acticity is Sensitive to 0001. This application claims priority to provisional U.S. the chemical inhibitor tetraiSopropylpyrophosphoramide application No. 60/344,295 filed Dec. 21, 2001 under 35 (also known as iso-OMPA), are called butyrylcholinest U.S.C. S 119(e), which is incorporated by reference. erases (BChE, EC 3.1.1.8). BChE is also known as pseudo cholinesterase or non-specific cholinesterase. Further clas FIELD OF THE INVENTION sifications of ChE’s are based on charge, hydrophobicity, 0002 The present invention provides methods for the interaction with membrane or extracellular structures, and large-scale production of recombinant butyrylcholinesterase Subunit composition. in cell culture, and in the milk and/or urine of transgenic 0006 Acetylcholinesterase (AChE), also known as true, mammals. The recombinant butyrylcholinesterases of this Specific, genuine, erythrocyte, red cell, or Type I ChE, is a invention can be used to treat and/or prevent organophoS membrane-bound glycoprotein and exists in Several molecu phate pesticide poisoning, nerve gas poisoning, cocaine lar forms. It is found in erythrocytes, nerve endings, lungs, intoxication, and Succinylcholine-induced apnea. Spleen, and the gray matter of the brain. Butyrylcholinest erase (BChE), also known as plasma, Serum, benzoyl, false, BACKGROUND OF THE INVENTION or Type II ChE, has more than eleven isoenzyme variants 0003) The general term cholinesterase (ChE) refers to a and preferentially uses butyrylcholine and benzoylcholine as family of enzymes involved in nerve impulse transmission. in vitro Substrates. BChE is found in mammalian blood The major function of ChE enzymes is to catalyze the plasma, liver, pancreas, intestinal mucosa, the white matter hydrolysis of the chemical compound acetylcholine at the of the central nervous System, Smooth muscle, and heart. cholinergic Synapses. Electrical Switching centers, called BChE is Sometimes referred to as Serum cholinesterase as Synapses, are found throughout the nervous Systems of opposed to red cell cholinesterase (AChE). humans, other vertebrates and insects. Muscles, glands, and 0007 AChE and BChE exist in parallel arrays of multiple neurons are Stimulated or inhibited by the constant firing of molecular forms composed of different numbers of catalytic Signals across these Synapses. Stimulating Signals are carried and non-catalytic Subunits. Both enzymes are composed of by the neurotransmitter acetylcholine, and discontinued by Subunits of about 600 amino acids each, and both are the action of ChE enzymes, which cause hydrolytic break glycosylated. AChE may be distinguished from the closely down of acetylcholine. These chemical reactions are going related BChE by its high specificity for the acetylcholine on all the time at a very fast rate, with acetylcholine causing substrate and sensitivity to selective inhibitors. While AChE Stimulation and ChE enzymes ending the Signals. The action is primarily used in the body to hydrolyze acetylcholine, the of ChE allows the muscle, gland, or nerve to return to its specific function of BChE is not as clear. BChE has no resting State, ready to receive another nerve impulse if need known specific natural Substrate, although it also hydrolyzes be. acetylcholine. 0004. If cholinesterase-inhibiting substances such as 0008. Despite the devastating effects of certain cholinest organophosphate compounds or carbamate insecticides or erase-inhibiting Substances on humans, these compounds are drugs are present, this System is thrown out of balance. not without therapeutic uses. Cholinesterase-inhibiting These cholinesterase-inhibiting Substances prevent the drugs are employed to treat a wide variety of diseases breakdown of acetylcholine, resulting in a buildup of ace including Alzheimer's and Parkinson's diseases, glaucoma, tylcholine, thereby causing hyperactivity of the nervous multiple Sclerosis, and myasthenia gravis. The cholinest System. Acetylcholine is not destroyed and continues to erase-inhibiting compound Succinyl choline is commonly Stimulate the muscarinic receptor sites (exocrine glands and used as a short-acting muscle relaxant in Surgical operations.